[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541605":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":24,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":24,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":24,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":24,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"St. Joseph's Hospital and Medical Center, Phoenix","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Gentamicin","EXPERIMENTAL","14.4 mg gentamicin dissolved in 30 mL 0f 0.9% saline administered BID",[13],"Drug: Gentamicin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","30 mL of 0.9% saline administered BID",[13],[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)",[9,15],null,[26],{"name":27,"affiliation":5,"role":28},"Hahn Soe-Lin, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Kristina M Kupanoff, PhD","CONTACT","602-406-5192","Kristina.Kupanoff@commonspirit.org",{"name":27,"role":32,"phone":36,"phoneExt":24,"email":37},"602-406-3874","Hahn.Soe-Lin@commonspirit.org",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"St. Jpseph's Hospital and Medical Center","RECRUITING","Phoenix","Arizona","85013","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-112.07404,33.44838,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":33,"phoneExt":24,"email":56},"Kristina Kupanoff, PhD","Kristina.Kupanoff@Commonspirit.org",{"type":58,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100541605","phase-4-gentamicin-bladder-instillation-on-cauti-100541605",false,"NCT06332040","Gentamicin Bladder Instillation on CAUTI","A Randomized Controlled Trial to Evaluate the Effectiveness of Gentamicin Bladder Instillation on CAUTI","Inclusion Criteria:\n\n1. age greater than 18\n2. admitted with a trauma, surgical, or neuro-critical care diagnosis\n3. indwelling foley catheter in place\n\nExclusion Criteria:\n\n1. Documented positive UA or Urine Culture within the past 7 days or upon admission\n2. Traumatic bladder injury\n3. Gross hematuria\n4. Chronic indwelling urethral or chronic suprapubic foley catheter\n5. allergy to gentamicin or similar aminoglycosides","ALL","18 Years",{"count":69,"type":70},400,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \\& Medicaid Services (CMS); however there is not consensus among clinicians on how to best prevent CAUTIs. We propose a prospective randomized controlled trial to test the efficacy of prophylactic gentamicin bladder irrigation in elimination of CAUTIs.",[76],"Catheter Infection","2025-07-08",{"date":79,"type":80},"2025-07-11","ACTUAL",{"date":82,"type":80},"2023-10-09",{"date":84,"type":70},"2026-10-08",{"name":5,"class":6},1]